Tag: Alpha-Synuclein
At the International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PD), a research team funded by The Michael J. Fox Foundation is anno...
A significant milestone in brain disease research was achieved early this week when the U.S. Food and Drug Administration (FDA) announced approval of...
Another therapy in the drug development pipeline has taken a step forward with the start of a new trial in nearly 600 people with Parkinson’s. Partn...
On April 22, 2020, the pharmaceutical company Roche announced results from the first part of the PASADENA study, a Phase II clinical trial (human stud...
Alpha-synuclein is a priority for The Michael J. Fox Foundation. We devote substantial resources to programs that help us better understand its role i...
The Parkinson’s therapeutic pipeline continues to grow as another therapy targeting the protein alpha-synuclein begins human studies. Earlier ...
Last week biotech Prothena announced the first participant has enrolled in its PASADENA study, a Phase II trial of its anti-alpha-synuclein antibody...
Alpha-synuclein — the protein that clumps in brain cells of people with Parkinson’s — is not only a therapeutic target but also may be a measure...
The first major study results from the Parkinson’s Progression Markers Initiative (PPMI) are highlighted in today’s edition of USA Today. The stu...